A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population-Reference-Cited by-全球学者库

A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population

Published:2015-11 Issue:17 Volume:16 Page:1943-1949
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Wang Fang¹²³,Mi Weifeng¹²,Ma Wenbin⁴,Ma Cuicui⁴,Yang Yongfeng⁵⁶,Zhang Hongxing⁵⁶,Du Bo⁷,Li Keqing⁷,Liu Chenxing¹²,Wang Lifang¹²,Lu Tianlan¹²,Zhang Hongyan¹²,Lv Luxian⁵⁶,Zhang Dai¹²,Yue Weihua¹²

Affiliation:

1. Peking University Sixth Hospital (Institute of Mental Health), Beijing 100191, China

2. Key Laboratory of Mental Health, Ministry of Health & National Clinical Research Center for Mental Health (Peking University), Beijing 100191, China

3. Beijing Children’s Hospital, Capital Medical University, Beijing 100191, China

4. Jinzhou Kangning Hospital, Jinzhou, Liaoning 121013, China

5. Department of Psychiatry of the Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453002, China

6. Henan Mental Hospital, Henan Key Lab of Biological Psychiatry, Xinxiang, Henan 453002, China

7. Hebei Mental Health Center, Baoding, Hebei 071000, China

Abstract

Aim: We carried out a pharmacogenomic study in order to identify susceptible genes for antipsychotics induced weight gain within the Chinese Han population. Materials & methods: We enrolled 216 patients with schizophrenia in our study. All of them underwent risperidone monotherapy, and fulfilled 4-week follow-up. Weight gain was measured before treatment and 4 weeks later. Seven hundred and sixty-eight SNPs from 85 genes were calculated for association with weight gain percentage. Results: Fifty-seven SNPs located at 16 genes with a p-value less than 0.05.4 SNPs located on serotonin transporter gene (solute carrier family 6, member 4, SLC6A4) remained significant after multitest correction (rs3813034, p = 0.000357, q = 0.08, rs1042173, rs4325622, rs9303628, p = 0.000451, q = 0.08). Conclusion: SLC6A4 might be susceptible gene for risperidone-induced weight gain within the Chinese Han population.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs.15.133

Reference35 articles.

1. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

2. Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?

3. Schizophrenia and increased risks of cardiovascular disease

4. Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database

5. Medication Adherence and Subjective Weight Perception in Patients with First-Episode Psychotic Disorder

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia;Frontiers in Psychiatry;2023-04-20

2. Rs9303628 and rs2054847 of SLC6A4 are protective factors for the onset of lifelong premature ejaculation among the Chinese population;Andrologia;2020-08-25

3. Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population;Neuroscience Bulletin;2019-01-03

4. New findings in pharmacogenetics of schizophrenia;Current Opinion in Psychiatry;2018-05

5. Pharmacogenomics in Psychiatric Practice;CLIN LAB MED;2016